These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36715093)

  • 21. Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment.
    Naderi N
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):207-209. PubMed ID: 32359040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of giant cell arteritis].
    Samson M; Greigert H; Bonnotte B
    Rev Prat; 2023 Apr; 73(4):395-399. PubMed ID: 37289152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vision loss in patients with giant cell arteritis treated with tocilizumab.
    Amsler J; Kysela I; Tappeiner C; Seitz L; Christ L; Scholz G; Stalder O; Kollert F; Reichenbach S; Villiger PM
    Arthritis Res Ther; 2021 Mar; 23(1):92. PubMed ID: 33752737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.
    Hellmich B; Águeda AF; Monti S; Luqmani R
    Curr Rheumatol Rep; 2020 Oct; 22(12):84. PubMed ID: 33044642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review.
    de Boysson H; Boutemy J; Creveuil C; Ollivier Y; Letellier P; Pagnoux C; Bienvenu B
    Semin Arthritis Rheum; 2013 Aug; 43(1):105-12. PubMed ID: 23453684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tocilizumab in the treatment of giant cell arteritis.
    Leuchten N; Aringer M
    Immunotherapy; 2018 Mar; 10(6):465-472. PubMed ID: 29504436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does Tocilizumab Influence Ophthalmic Outcomes in Giant Cell Arteritis?
    Bouffard MA; Prasad S; Unizony S; Costello F
    J Neuroophthalmol; 2022 Jun; 42(2):173-179. PubMed ID: 35482901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Giant cell arteritis and innovative treatments.
    Costanzo G; Ledda AG; Sambugaro G
    Curr Opin Allergy Clin Immunol; 2023 Aug; 23(4):327-333. PubMed ID: 37357797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic approach to giant cell arteritis.
    Masson C
    Joint Bone Spine; 2012 May; 79(3):219-27. PubMed ID: 22119350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Large-vessel giant cell arteritis: diagnosis, monitoring and management.
    Koster MJ; Matteson EL; Warrington KJ
    Rheumatology (Oxford); 2018 Feb; 57(suppl_2):ii32-ii42. PubMed ID: 29982778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of giant cell arteritis - current approach and new possibilities].
    Videman J; Skácelová M; Horák P; Skoumalová A; Hraboš D
    Vnitr Lek; 2022; 68(5):266-272. PubMed ID: 36283815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy.
    Higashida-Konishi M; Akiyama M; Shimada T; Hama S; Oshige T; Izumi K; Oshima H; Okano Y
    Rheumatol Int; 2023 Mar; 43(3):545-549. PubMed ID: 36152056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
    Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study.
    Schönau V; Roth J; Tascilar K; Corte G; Manger B; Rech J; Schmidt D; Cavallaro A; Uder M; Crescentini F; Boiardi L; Casali M; Spaggiari L; Galli E; Kuwert T; Versari A; Salvarani C; Schett G; Muratore F
    Rheumatology (Oxford); 2021 Aug; 60(8):3851-3861. PubMed ID: 33831144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tocilizumab in giant cell arteritis: an update for the clinician.
    Ford JA; Gewurz D; Gewurz-Singer O
    Curr Opin Rheumatol; 2023 May; 35(3):135-140. PubMed ID: 36912060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing treatment options for large vessel vasculitis.
    Macaluso F; Marvisi C; Castrignanò P; Pipitone N; Salvarani C
    Expert Rev Clin Immunol; 2022 Aug; 18(8):793-805. PubMed ID: 35714219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Giant Cell Arteritis: Beyond Corticosteroids.
    Steel L; Khan A; Dasgupta B
    Drugs Aging; 2015 Aug; 32(8):591-9. PubMed ID: 26239828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Giant cell arteritis in patients with systemic sclerosis: a case series.
    Guarda M; Roy A; Burke M; Warrington KJ; Koster MJ
    Clin Exp Rheumatol; 2024 Apr; 42(4):859-863. PubMed ID: 38526007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
    Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
    Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.
    Unizony S; McCulley TJ; Spiera R; Pei J; Sidiropoulos PN; Best JH; Birchwood C; Pavlov A; Stone JH
    Arthritis Res Ther; 2021 Jan; 23(1):8. PubMed ID: 33407817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.